Home
Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era
Loading Inventory...
Barnes and Noble
Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era
Current price: $105.00
Barnes and Noble
Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era
Current price: $105.00
Loading Inventory...
Size: OS
*Product Information may vary - to confirm product availability, pricing, and additional information please contact Barnes and Noble
Focusing on the period between the 1970s and the present,
is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences.The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy.At the very core of the new post-industrial economy is the transformation of biological life into surplus value.
offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.